|
1
|
Li C, Liu X, Adhikari BK, Chen L, Liu W,
Wang Y and Zhang H: The role of epicardial adipose tissue
dysfunction in cardiovascular diseases: An overview of
pathophysiology, evaluation, and management. Front Endocrinol
(Lausanne). 14(1167952)2023.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Libby P: The changing landscape of
atherosclerosis. Nature. 592:524–533. 2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ganda OP, Bhatt DL, Mason RP, Miller M and
Boden WE: Unmet need for adjunctive dyslipidemia therapy in
hypertriglyceridemia management. J Am Coll Cardiol. 72:330–343.
2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Triglyceride Coronary Disease Genetics
Consortium and Emerging Risk Factors Collaboration. Sarwar N,
Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E,
Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, et al:
Triglyceride-mediated pathways and coronary disease: Collaborative
analysis of 101 studies. Lancet. 375:1634–1639. 2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Karlson BW, Palmer MK, Nicholls SJ,
Lundman P and Barter PJ: A VOYAGER meta-analysis of the impact of
statin therapy on low-density lipoprotein cholesterol and
triglyceride levels in patients with hypertriglyceridemia. Am J
Cardiol. 117:1444–1448. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Dong SJ, Bian JL, Chen HS and Zhang RS: A
systematic review of omega-3 fatty acids combined with statins for
treatment of dyslipidemia. J Clin Pharmacotherapy. 20:21–28.
2019.
|
|
7
|
Mason RP, Sherratt SCR and Eckel RH:
Rationale for different formulations of omega-3 fatty acids leading
to differences in residual cardiovascular risk reduction.
Metabolism. 130(155161)2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Mason RP and Eckel RH: Mechanistic
insights from REDUCE-IT STRENGTHen the case against triglyceride
lowering as a strategy for cardiovascular disease risk reduction.
Am J Med. 134:1085–1090. 2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Tadic M, Sala C, Grassi G, Mancia G,
Taddei S, Rottbauer W and Cuspidi C: Omega-3 fatty acids and
coronary artery disease: More questions than answers. J Clin Med.
10(2495)2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Saini RK and Keum YS: Omega-3 and omega-6
polyunsaturated fatty acids: Dietary sources, metabolism, and
significance-a review. Life Sci. 203:255–267. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Sheikh O, Vande Hei AG, Battisha A, Hammad
T, Pham S and Chilton R: Cardiovascular, electrophysiologic, and
hematologic effects of omega-3 fatty acids beyond reducing
hypertriglyceridemia: As it pertains to the recently published
REDUCE-IT trial. Cardiovasc Diabetol. 18(84)2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Baker EJ, Miles EA, Burdge GC, Yaqoob P
and Calder PC: Metabolism and functional effects of plant-derived
omega-3 fatty acids in humans. Prog Lipid Res. 64:30–56.
2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Innes JK and Calder PC: Marine omega-3
(N-3) fatty acids for cardiovascular health: An update for 2020.
Int J Mol Sci. 21(1362)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Calder PC: Very long-chain n-3 fatty acids
and human health: Fact, fiction and the future. Proc Nutr Soc.
77:52–72. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Dyall SC: Long-chain omega-3 fatty acids
and the brain: A review of the independent and shared effects of
EPA, DPA and DHA. Front Aging Neurosci. 7(52)2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Mason RP, Sherratt SCR and Eckel RH:
Omega-3-fatty acids: Do they prevent cardiovascular disease? Best
Pract Res Clin Endocrinol Metab. 37(101681)2023.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Nordestgaard BG: Triglyceride-rich
lipoproteins and atherosclerotic cardiovascular disease: New
insights from epidemiology, genetics, and biology. Circ Res.
118:547–563. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ginsberg HN, Packard CJ, Chapman MJ, Borén
J, Aguilar-Salinas CA, Averna M, Ference BA, Gaudet D, Hegele RA,
Kersten S, et al: Triglyceride-rich lipoproteins and their
remnants: metabolic insights, role in atherosclerotic
cardiovascular disease, and emerging therapeutic strategies-a
consensus statement from the European atherosclerosis society. Eur
Heart J. 42:4791–4806. 2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Dubois V, Eeckhoute J, Lefebvre P and
Staels B: Distinct but complementary contributions of PPAR isotypes
to energy homeostasis. J Clin Invest. 127:1202–1214.
2017.PubMed/NCBI View
Article : Google Scholar
|
|
20
|
Derosa G, Sahebkar A and Maffioli P: The
role of various peroxisome proliferator-activated receptors and
their ligands in clinical practice. J Cell Physiol. 233:153–161.
2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Jump DB: N-3 polyunsaturated fatty acid
regulation of hepatic gene transcription. Curr Opin Lipidol.
19:242–247. 2008.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Mason RP, Jacob RF, Shrivastava S,
Sherratt SCR and Chattopadhyay A: Eicosapentaenoic acid reduces
membrane fluidity, inhibits cholesterol domain formation, and
normalizes bilayer width in atherosclerotic-like model membranes.
Biochim Biophys Acta. 1858:3131–3140. 2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Sherratt SCR, Libby P, Bhatt DL and Mason
RP: A biological rationale for the disparate effects of omega-3
fatty acids on cardiovascular disease outcomes. Prostaglandins
Leukot Essent Fatty Acids. 182(102450)2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Gutiérrez S, Svahn SL and Johansson ME:
Effects of omega-3 fatty acids on immune cells. Int J Mol Sci.
20(5028)2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Lu LW, Quek SY, Lu SP and Chen JH:
Potential benefits of omega-3 polyunsaturated fatty acids (N3PUFAs)
on cardiovascular health associated with COVID-19: An update for
2023. Metabolites. 13(630)2023.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Oner F, Alvarez C, Yaghmoor W, Stephens D,
Hasturk H, Firatli E and Kantarci A: Resolvin E1 regulates Th17
function and T cell activation. Front Immunol.
12(637983)2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Meydani SN, Endres S, Woods MM, Goldin BR,
Soo C, Morrill-Labrode A, Dinarello CA and Gorbach SL: Oral (n-3)
fatty acid supplementation suppresses cytokine production and
lymphocyte proliferation: Comparison between young and older women.
J Nutr. 121:547–555. 1991.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Williams-Bey Y, Boularan C, Vural A, Huang
NN, Hwang IY, Shan-Shi C and Kehrl JH: Omega-3 free fatty acids
suppress macrophage inflammasome activation by inhibiting NF-κB
activation and enhancing autophagy. PLoS One.
9(e97957)2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Sung J, Jeon H, Kim IH, Jeong HS and Lee
J: Anti-inflammatory effects of stearidonic acid mediated by
suppression of NF-κB and MAP-kinase pathways in macrophages.
Lipids. 52:781–787. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Oh DY, Talukdar S, Bae EJ, Imamura T,
Morinaga H, Fan W, Li P, Lu WJ, Watkins SM and Olefsky JM: GPR120
is an omega-3 fatty acid receptor mediating potent
anti-inflammatory and insulin-sensitizing effects. Cell.
142:687–698. 2010.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Reilly NA, Lutgens E, Kuiper J, Heijmans
BT and Jukema JW: Effects of fatty acids on T cell function: Role
in atherosclerosis. Nat Rev Cardiol. 18:824–837. 2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Yubero-Serrano EM, Fernandez-Gandara C,
Garcia-Rios A, Rangel-Zuñiga OA, Gutierrez-Mariscal FM, Torres-Peña
JD, Marin C, Lopez-Moreno J, Castaño JP, Delgado-Lista J, et al:
Mediterranean diet and endothelial function in patients with
coronary heart disease: An analysis of the CORDIOPREV randomized
controlled trial. PLoS Med. 17(e1003282)2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Vanhoutte PM, Shimokawa H, Feletou M and
Tang EH: Endothelial dysfunction and vascular disease-a 30th
anniversary update. Acta Physiol (Oxf). 219:22–96. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Mason RP, Dawoud H, Jacob RF, Sherratt SCR
and Malinski T: Eicosapentaenoic acid improves endothelial function
and nitric oxide bioavailability in a manner that is enhanced in
combination with a statin. Biomed Pharmacother. 103:1231–1237.
2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Dang TA, Schunkert H and Kessler T: cGMP
signaling in cardiovascular diseases: Linking genotype and
phenotype. J Cardiovasc Pharmacol. 75:516–525. 2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Burr ML, Fehily AM, Gilbert JF, Rogers S,
Holliday RM, Sweetnam PM, Elwood PC and Deadman NM: Effects of
changes in fat, fish, and fibre intakes on death and myocardial
reinfarction: Diet and reinfarction trial (DART). Lancet.
2:757–761. 1989.PubMed/NCBI View Article : Google Scholar
|
|
37
|
No authors listed. Dietary supplementation
with n-3 polyunsaturated fatty acids and vitamin E after myocardial
infarction: Results of the GISSI-Prevenzione trial. Gruppo Italiano
per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet.
354:447–455. 1999.PubMed/NCBI
|
|
38
|
Yokoyama M, Origasa H, Matsuzaki M,
Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H,
Itakura H, et al: Effects of eicosapentaenoic acid on major
coronary events in hypercholesterolaemic patients (JELIS): A
randomised open-label, blinded endpoint analysis. Lancet.
369:1090–1098. 2007.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Rauch B, Schiele R, Schneider S, Diller F,
Victor N, Gohlke H, Gottwik M, Steinbeck G, Del Castillo U, Sack R,
et al: OMEGA, a randomized, placebo-controlled trial to test the
effect of highly purified omega-3 fatty acids on top of modern
guideline-adjusted therapy after myocardial infarction.
Circulation. 122:2152–2159. 2010.PubMed/NCBI View Article : Google Scholar
|
|
40
|
ORIGIN Trial Investigators. Bosch J,
Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP,
Probstfield J, Ramachandran A, et al: N-3 fatty acids and
cardiovascular outcomes in patients with dysglycemia. N Engl J Med.
367:309–318. 2012.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Risk and Prevention Study Collaborative
Group. Roncaglioni MC, Tombesi M, Avanzini F, Barlera S, Caimi V,
Longoni P, Marzona I, Milani V, Silletta MG, et al: N-3 fatty acids
in patients with multiple cardiovascular risk factors. N Engl J
Med. 368:1800–1808. 2013.PubMed/NCBI View Article : Google Scholar
|
|
42
|
ASCEND Study Collaborative Group. Bowman
L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K,
Aung T, Haynes R, et al: Effects of n-3 fatty acid supplements in
diabetes mellitus. N Engl J Med. 379:1540–1550. 2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Manson JE, Cook NR, Lee IM, Christen W,
Bassuk SS, Mora S, Gibson H, Albert CM, Gordon D, Copeland T, et
al: Marine n-3 fatty acids and prevention of cardiovascular disease
and cancer. N Engl J Med. 380:23–32. 2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Bhatt DL, Steg PG, Miller M, Brinton EA,
Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz
C, et al: Cardiovascular risk reduction with icosapent ethyl for
hypertriglyceridemia. N Engl J Med. 380:11–22. 2019.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Nicholls SJ, Lincoff AM, Garcia M, Bash D,
Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W,
McGuire DK, et al: Effect of high-dose omega-3 fatty acids vs corn
oil on major adverse cardiovascular events in patients at high
cardiovascular risk: The STRENGTH randomized clinical trial. JAMA.
324:2268–2280. 2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Kalstad AA, Myhre PL, Laake K, Tveit SH,
Schmidt EB, Smith P, Nilsen DWT, Tveit A, Fagerland MW, Solheim S,
et al: Effects of n-3 fatty acid supplements in elderly patients
after myocardial infarction: A randomized, controlled trial.
Circulation. 143:528–539. 2021.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Mach F, Baigent C, Catapano AL, Koskinas
KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V,
Ference BA, et al: 2019 ESC/EAS guidelines for the management of
dyslipidaemias: Lipid modification to reduce cardiovascular risk.
Eur Heart J. 41:111–188. 2020.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Chinese Society of Cardiology of Chinese
Medical Association, Cardiovascular Disease Prevention and
Rehabilitation Committee of Chinese Association of Rehabilitation
Medicine, Cardiovascular Disease Committee of Chinese Association
of Gerontology and Geriatrics, Thrombosis Prevention and Treatment
Committee of Chinese Medical Doctor Association. Chinese Guideline
on the primary prevention of cardiovascular diseases. Zhonghua Xin
Xue Guan Bing Za Zhi. 48:1000–1038. 2020.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
49
|
Working Group of the Chinese Expert
Consensus on Secondary Prevention after Coronary Artery Bypass
Surgery, The Task Force for Coronary Artery Disease of Chinese
Association of Cardiovascular Surgeons and The Task Force for
Coronary Artery Disease of Chinese Society of Thoracic and
Cardiovascular Surgery. Chinese expert consensus on secondary
prevention after coronary artery bypass surgery (2020). Chin J Thor
Cardi Sur. 37:193–201. 2021.(In Chinese).
|
|
50
|
Hypertension Group, Chinese Society of
Cardiology, Editorial Board of Chinese Journal of Cardiology.
Expert consensus on comprehensive management of blood pressure and
lipids in Chinese patients with hypertension. Zhonghua Xin Xue Guan
Bing Za Zhi. 49:554–563. 2021.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
51
|
Centre for Capacity Building and
Continuing Education, National Health Commission. Expert consensus
on diagnosis and treatment of cardiovascular diseases in diabetic
patients. Chin J Inter Med. 60:421–437. 2021.(In Chinese).
|
|
52
|
Kleindorfer DO, Towfighi A, Chaturvedi S,
Cockroft KM, Gutierrez J, Lombardi-Hill D, Kamel H, Kernan WN,
Kittner SJ, Leira EC, et al: 2021 Guideline for the prevention of
stroke in patients with stroke and transient ischemic attack: A
guideline from the American heart association/American stroke
association. Stroke. 52:e364–e467. 2021.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Virani SS, Morris PB, Agarwala A,
Ballantyne CM, Birtcher KK, Kris-Etherton PM, Ladden-Stirling AB,
Miller M, Orringer CE and Stone NJ: 2021 ACC expert consensus
decision pathway on the management of ASCVD risk reduction in
patients with persistent hypertriglyceridemia: A report of the
American college of cardiology solution set oversight committee. J
Am Coll Cardiol. 78:960–993. 2021.PubMed/NCBI View Article : Google Scholar
|
|
54
|
American Diabetes Association Professional
Practice Committee. 10. Cardiovascular disease and risk management:
Standards of medical care in diabetes-2022. Diabetes Care. 45
(Suppl 1):S144–S174. 2022.PubMed/NCBI View Article : Google Scholar
|
|
55
|
National Committee of Cardiometabolic
Medicine Specialists Committee. The role of omega-3 fatty acids in
the prevention and treatment of cardiovascular diseases. Chin J
Cir. 38:116–130. 2019.(In Chinese).
|
|
56
|
Li JJ, Zhao SP, Zhao D, Lu GP, Peng DQ,
Liu J, Chen ZY, Guo YL, Wu NQ, Yan SK, et al: 2023 China Guidelines
for Lipid Management. J Geriatr Cardiol. 20:621–663.
2023.PubMed/NCBI View Article : Google Scholar
|
